Aktiesnakken — August 2010
-
men, det bliver utrolig svært at håndhæve i praksis, hvis du har en test hvor du kan se andet end hvad patentet
-
siger du må se, vil du så reagere på det
-
-
præcis... jeg vil lige gemme den til imorgen, så kan jeg få en basse samtidig
-
men potentialet er der jo, jeg kan godt i første omgang som investor nøjes med 175mio årlige test
-
så kan vi købe de selskaber der skulle have nogle patenter der stod i vejen
-
vi har og tjener gode penge: http://www.dr.dk/Nyheder/Penge/2010/08/06/220823.htm?rss=true
-
til Bioporto-folk : The final Battle https://register.epoline.org/espacenet/application?tab=doclist&number=EP05820913&filter=ALL
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind